Advertisement
Letter to the Editor| Volume 163, ISSUE 3, P335-337, March 10, 2013

Download started.

Ok

Galectin-3: Relation to infarct scar and left ventricular function after myocardial infarction

Published:July 16, 2012DOI:https://doi.org/10.1016/j.ijcard.2012.06.087
Galectin-3: Relation to infarct scar and left ventricular function after myocardial infarction
Previous ArticleRETRACTED: Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury
Next ArticleImpact of caffeine ingestion on ventricular function in coronary artery disease
      Elevated serum levels of galectin-3, a member of the lectin family, have recently been reported in heart failure patients, as well as in animal models of heart failure [
      • de Boer R.A.
      • Voors A.A.
      • Muntendam P.
      • van Gilst W.H.
      • van Veldhuisen D.J.
      Galectin-3: a novel mediator of heart failure development and progression.
      Eur J Heart Fail. 2009; 11: 811-817
      ,
      • Sharma U.C.
      • Pokharel S.
      • van Brakel T.L.
      • et al.
      Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
      Circulation. 2004; 110: 3121-3128
      ,
      • Sharma U.
      • Rhaleb N.E.
      • Pokharel S.
      • et al.
      Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.
      Am J Physiol Heart Circ Physiol. 2008; 294: H1226-H1232
      • Conroy R.M.
      • Pyörälä K.
      • Fitzgerald A.P.
      987–1003
      Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
      Eur Heart J. 2003; 24: 987-1003
      ]. Apart from cardiac remodelling, upregulation of galectin-3 expression and release has also been associated with several other human fibrotic conditions including liver cirrhosis, idiopathic lung fibrosis, pancreatitis and renal failure. Therefore, this lectin is thought to play some regulatory role between inflammation and fibrosis [
      • de Boer R.A.
      • Voors A.A.
      • Muntendam P.
      • van Gilst W.H.
      • van Veldhuisen D.J.
      Galectin-3: a novel mediator of heart failure development and progression.
      Eur J Heart Fail. 2009; 11: 811-817
      ]. Its direct mediation of profibrotic pathways such as cell adhesion and proliferation suggests that galectin-3 is involved in the development of heart failure [
      • Dumic J.
      • Dabelic S.
      • Flögel M.
      Galectin-3: an open-ended story.
      Biochim Biophys Acta. Apr 2006; 1760 ([Epub 2006 Jan 18. Review]): 616-635
      ,
      • Yang R.Y.
      • Rabinovich G.A.
      • Liu F.T.
      Galectins: structure, function and therapeutic potential.
      Expert Rev Mol Med. Jun 13 2008; 10: e17
      ]. After acute myocardial infarction (AMI), fibrosis and tissue remodelling are the leading causes for the development of heart failure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • de Boer R.A.
        • Voors A.A.
        • Muntendam P.
        • van Gilst W.H.
        • van Veldhuisen D.J.
        Galectin-3: a novel mediator of heart failure development and progression.
        Eur J Heart Fail. 2009; 11: 811-817
        View in Article
        • Sharma U.C.
        • Pokharel S.
        • van Brakel T.L.
        • et al.
        Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
        Circulation. 2004; 110: 3121-3128
        View in Article
        • Sharma U.
        • Rhaleb N.E.
        • Pokharel S.
        • et al.
        Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.
        Am J Physiol Heart Circ Physiol. 2008; 294: H1226-H1232
        View in Article
        • Conroy R.M.
        • Pyörälä K.
        • Fitzgerald A.P.
        • 987–1003
        Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
        Eur Heart J. 2003; 24: 987-1003
        View in Article
        • Dumic J.
        • Dabelic S.
        • Flögel M.
        Galectin-3: an open-ended story.
        Biochim Biophys Acta. Apr 2006; 1760 ([Epub 2006 Jan 18. Review]): 616-635
        View in Article
        • Yang R.Y.
        • Rabinovich G.A.
        • Liu F.T.
        Galectins: structure, function and therapeutic potential.
        Expert Rev Mol Med. Jun 13 2008; 10: e17
        View in Article
        • Kim R.J.
        • Fieno D.S.
        • Parrish T.B.
        • et al.
        Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.
        Circulation. 1999; 100: 1992-2002
        View in Article
        • Ibrahim T.
        • Nekolla S.G.
        • Hornke M.
        • et al.
        Quantitative measurement of infarct size by contrast-enhanced magnetic resonance imaging early after acute myocardial infarction: comparison with single-photon emission tomography using Tc99m-sestamibi.
        J Am Coll Cardiol. 2005; 45: 544-552
        View in Article
        • Klug G.
        • Trieb T.
        • Schocke M.
        • et al.
        Quantification of regional functional improvement of infarcted myocardium after primary PTCA by contrast-enhanced magnetic resonance imaging.
        J Magn Reson Imaging. Feb 2009; 29: 298-304
        View in Article
        • Mayr A.
        • Mair J.
        • Schocke M.
        • et al.
        Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function.
        Int J Cardiol. Feb 17 2011; 147 ([Epub 2009 Nov 7]): 118-123
        View in Article
        • Mayr A.
        • Klug G.
        • Schocke M.
        • et al.
        Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers.
        Int J Cardiol. Jun 14 2012; 157 ([Epub 2011 Jan 15]): 391-396
        View in Article
        • Grandin E.W.
        • Jarolim P.
        • Murphy S.A.
        • et al.
        Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
        Clin Chem. Jan 2012; 58 ([Epub 2011 Nov 22]): 267-273
        View in Article
        • Shah R.V.
        • Chen-Tournoux A.A.
        • Picard M.H.
        • van Kimmenade R.R.
        • Januzzi J.L.
        Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.
        Eur J Heart Fail. Aug 2010; 12 ([Epub 2010 Jun 5]): 826-832
        View in Article
        • Tang W.H.
        • Shrestha K.
        • Shao Z.
        • et al.
        Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.
        Am J Cardiol. Aug 1 2011; 108 ([Epub 2011 May 19]): 385-390
        View in Article
        • van Kimmenade R.R.
        • Januzzi Jr., J.L.
        • Ellinor P.T.
        • et al.
        Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
        J Am Coll Cardiol. Sep 19 2006; 48 ([Epub 2006 Aug 28]): 1217-1224
        View in Article
        • Felker G.M.
        • Fiuzat M.
        • Shaw L.K.
        • et al.
        Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.
        Circ Heart Fail. Jan 1 2012; 5 ([Epub 2011 Oct 20]): 72-78
        View in Article
        • Tjeerdsma G.
        • de Boer R.A.
        • Boomsma F.
        • van den Berg M.P.
        • Pinto Y.M.
        • van Veldhuisen D.J.
        Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure.
        Int J Cardiol. Dec 2002; 86 ([discussion 149–52]): 143-149
        View in Article
        • Milting H.
        • Ellinghaus P.
        • Seewald M.
        • et al.
        Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
        J Heart Lung Transplant. Jun 2008; 27: 589-596
        View in Article
        • Coats A.J.
        Ethical authorship and publishing.
        Int J Cardiol. 2009; 131: 149-150
        View in Article

      Article info

      Publication history

      Published online: July 16, 2012
      Accepted: June 24, 2012
      Received: May 29, 2012

      Identification

      DOI: https://doi.org/10.1016/j.ijcard.2012.06.087

      Copyright

      © 2012 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX